“…More recent studies have explored genome copy number alterations in invasive breast carcinomas using array-based CGH in relation to tumor pathology, and would therefore have the potential to validate association of 8q22 gains with Grade 3 tumors (Loo et al, 2004;Somiari et al, 2004;Callagy et al, 2005;Naylor et al, 2005;Nessling et al, 2005;Varma et al, 2005;Bergamaschi et al, 2006;Chin et al, 2006Chin et al, , 2007Fridlyand et al, 2006;Stange et al, 2006;Pierga et al, 2007). However, while some of these studies did not differentiate between Grade 1, Grade 2, and Grade 3 tumors (Loo et al, 2004;Naylor et al, 2005;Nessling et al, 2005;Varma et al, 2005;Bergamaschi et al, 2006;Fridlyand et al, 2006), other studies performed array CGH using clone sets that did not contain DNA sequence representation within 5 Mb of RP11-10G10 (Somiari et al, 2004;Callagy et al, 2005;Chin et al, 2007).…”